Aumilto Silva, Medical Oncologist and Clinical Research at Hospital Santa Catarina Paulista, shared a post on X:
“PATINA Trial
Population: HR-positive / HER2-positive metastatic breast cancer Patients without progression after induction chemo + anti-HER2 therapy
Design: Phase 3, randomized Maintenance anti-HER2 + endocrine therapy with vs without palbociclib
Primary endpoint: PFS
Key Results
Median PFS:
- Palbociclib arm: 44.3 months
- Standard therapy: 29.1 months
- HR 0.75 (95% CI 0.59–0.96), P=0.02
~15-month absolute PFS gain with CDK4/6 inhibition
Clinical benefit rate:
- 88.9% vs 80.9%
Confirmed response rate:
- 32.9% vs 24.8%
Overall survival:
- Immature at analysis (HR 0.86); final OS pending.
Why this matters?
Rather than escalating to more intensive therapies, PATINA shows that optimizing maintenance treatment can achieve long-term disease control. For patients who respond to induction therapy, adding palbociclib offers a way to prolong remission with an oral, biologically driven approach.”
Title: Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Authors: Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Travis Dockter, Xavier Gonzàlez Farré, Prudence A. Francis, Filipa Lynce, Jane Lanzillotti, Carter DuFrane, Anna Wall, Carrie Strand, Ian Krop, Ines Vaz-Luis, Debu Tripathy, Sherene Loi, Aleix Prat, Matthew Goetz, Santiago Escrivá-de-Romaní, David Porter, Jennifer Spoenlein, Daniel G. Stover, Sagar Sardesai, Pierre Heudel, Maria Koehler, Cynthia Huang Bartlett, Ariadna Holynskyj, Prashanth Gopalakrishna, Eric Gauthier, Suzette Delaloge, Kathy Miller, Eric P. Winer, Luca Gianni, Ann H. Partridge, Angela DeMichele, Lisa A. Carey
Read The Full Article.
More post featuring Aumilto Silva on OncoDaily.